941 regulatory filings were published by NSE- and BSE-listed companies on 21 March 2026 — showing page 10 of 10.
Zydus Lifesciences Ltd · ZYDUSLIFE · BSE ·
Announced the launch of Semaglutide Injection (brands: SEMAGLYN™, MASHEMA™, ALTERME™) for Type 2 Diabetes and Obesity in India, following patent expiry. The product will be delivered via an innovative, reusable multi-dose pen, for which the company holds exclusive rights, aiming…
Zydus Lifesciences Ltd · ZYDUSLIFE · BSE ·
**Product Launch:** The company has launched Semaglutide Injection in India for the treatment of Type 2 Diabetes and Obesity. **Key Innovation:** The drug is delivered via an exclusive, reusable multi-dose pen, designed to improve patient convenience and significantly lower the o…
Delhivery Ltd · DELHIVERY · BSE ·
• **Merger Approved:** The National Company Law Tribunal (NCLT) has sanctioned the scheme to merge two wholly-owned subsidiaries, Spoton Logistics and Spoton Supply Chain, into Delhivery. • **Key Date:** The "Appointed Date" for the amalgamation, from which all assets and liabili…
Delhivery Ltd · DELHIVERY · BSE ·
The National Company Law Tribunal (NCLT) has approved the merger of two wholly-owned subsidiaries, Spoton Logistics Pvt. Ltd. and Spoton Supply Chain Solutions Pvt. Ltd., into Delhivery Ltd. The Appointed Date for the amalgamation is set for April 1, 2025. No new shares will be i…
Dr Reddys Laboratories Ltd · DRREDDY · BSE ·
• **Product Launch:** Announced the launch of 'Obeda®', the first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for managing Type 2 Diabetes. • **First-Mover Advantage:** Marks a "Day-1 entry" into the high-growth GLP-1 therapy market, targeting…
Dr Reddys Laboratories Ltd · DRREDDY · BSE ·
• **Product Launch:** Announced the launch of 'Obeda®', India's first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for Type 2 Diabetes. • **Strategic Entry:** Marks a significant day-1 entry into the high-growth GLP-1 market upon patent expiry,…
Dr Reddys Laboratories Ltd · DRREDDY · BSE ·
Announced the launch of 'Obeda®', the first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for Type 2 Diabetes. The product is priced at ₹ 4,200 per month, aiming to make the advanced therapy more affordable in a market with over 101 million adult…
Radhagobind Commercial Ltd · 539673 · BSE ·
The company is currently under the Corporate Insolvency Resolution Process (CIRP), indicating severe financial distress. The 5th meeting of the Committee of Creditors (COC) is scheduled for February 5, 2026, to discuss the progress of the insolvency proceedings. Key agenda items…
Radhagobind Commercial Ltd · 539673 · BSE ·
The company, currently under Corporate Insolvency Resolution Process (CIRP), filed a notice for its 5th Committee of Creditors (CoC) meeting. <b>RED FLAG:</b> The notice for the meeting held on Feb 5, 2026, was filed significantly late on March 21, 2026, a compliance breach. <b>M…
Lemon Tree Hotels Limited · LEMONTREE · NSE ·
• Freyan Jamshed Desai has resigned from the position of Non-Executive Non-Independent Director. • The effective date of the resignation is listed as March 20, 2026. • **Red Flag:** The filing and resignation dates are set in the future, which is highly unusual and likely a data…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
<b>Top Ratings Reaffirmed:</b> CRISIL has reaffirmed its highest long-term rating of 'CRISIL AAA/Stable' and short-term rating of 'CRISIL A1+', indicating a very strong degree of safety for financial obligations. <b>Key Drivers:</b> The rating is underpinned by strong promoter su…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CRISIL has reaffirmed the company's highest long-term rating of `CRISIL AAA/Stable` and short-term rating of `CRISIL A1+`, citing strong strategic and financial support from the Poonawalla promoter group. A new rating of `CRISIL AA+/Stable` has been assigned to the proposed ₹1,50…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CRISIL has reaffirmed its highest long-term rating of `CRISIL AAA/Stable` on the company's bank facilities and most debt instruments, and assigned a `CRISIL AA+/Stable` rating to new Perpetual Bonds worth ₹1,500 Crore. The rating is driven by strong promoter support from the Poon…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating on the company's long-term bank facilities and debt, citing strong promoter support from the Cyrus Poonawalla group. Assets Under Management (AUM) showed strong growth, reaching ₹55,017 crore as of December 31, 202…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's long-term rating at 'CARE AAA; Stable', signifying the highest degree of safety. A new Perpetual Debt instrument of ₹1,500 Cr was assigned a 'CARE AA+; Stable' rating. The rating is driven by strong promoter support from the Cyrus Poonawa…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's highest credit rating of 'CARE AAA; Stable' on its long-term bank facilities and NCDs, citing strong promoter support and healthy financial flexibility. Assets Under Management (AUM) showed robust growth, more than doubling from ₹25,003 C…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CRISIL has reaffirmed its highest rating of 'CRISIL AAA/Stable' on the company's long-term bank facilities and NCDs, and 'CRISIL A1+' on its short-term instruments. A new rating of 'CRISIL AA+/Stable' has been assigned to the company's Perpetual Bonds worth ₹1,500 Crore, facilita…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
**Top-Tier Ratings Reaffirmed:** CRISIL has reaffirmed the company's highest long-term rating of `CRISIL AAA/Stable` and short-term rating of `CRISIL A1+`. A new `CRISIL AA+/Stable` rating was assigned to Perpetual Bonds worth ₹1,500 crore. **Strong Performance & Turnaround:** Th…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CRISIL reaffirmed its highest long-term rating of <b>'CRISIL AAA/Stable'</b> on the company's bank facilities and debt instruments, and the highest short-term rating of <b>'CRISIL A1+'</b>. The rating is driven by strong promoter support from the Poonawalla group, healthy capital…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's long-term bank facilities and NCDs at 'CARE AAA; Stable', signifying the highest degree of safety. The outlook remains "Stable". A new rating of 'CARE AA+; Stable' has been assigned to Perpetual Debt instruments worth ₹1,500 crore. The co…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's top-tier long-term rating at 'CARE AAA; Stable' and short-term rating at 'CARE A1+', citing strong promoter support. The promoter group (Cyrus Poonawalla) infused an additional <b>₹1,500 crore</b> in equity, reinforcing the company's capi…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
<b>Credit Rating Reaffirmed:</b> CARE Ratings has reaffirmed the highest rating of 'CARE AAA; Stable' for long-term facilities and 'CARE A1+' for short-term instruments. A new Perpetual Debt instrument of ₹1,500 crore was also assigned a 'CARE AA+; Stable' rating. <b>Strong AUM G…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
• <b>Top Rating Reaffirmed:</b> CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating for the company's long-term facilities, citing strong promoter support and healthy capitalisation. A new rating of 'CARE AA+; Stable' was assigned to a Perpetual Debt instrument. • <…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
CARE Ratings has reaffirmed the company's long-term rating at <b>'CARE AAA; Stable'</b> and short-term rating at <b>'CARE A1+'</b>, signifying the highest degree of safety. A new rating of <b>'CARE AA+; Stable'</b> was assigned to a new Perpetual Debt instrument worth ₹1,500 cror…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
• CARE Ratings has reaffirmed the highest credit rating of 'CARE AAA; Stable' for the company's long-term debt and 'CARE A1+' for its short-term instruments. • The company reported strong Assets Under Management (AUM) growth, reaching ₹55,017 crore as of Dec 2025, and is targetin…
Glenmark Pharmaceuticals Limited · GLENMARK · NSE ·
Announced the launch of GLIPIQ® (Semaglutide) in India for the management of Type 2 Diabetes. Aims to set a new benchmark in affordability, with the weekly cost of therapy starting at ₹325. The product has received approval from India's drug regulator (CDSCO) following a Phase II…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
<b>Top-Tier Rating Reaffirmed:</b> CARE Ratings has reaffirmed its highest credit rating of 'CARE AAA; Stable' for long-term facilities and 'CARE A1+' for short-term instruments, signaling maximum safety and creditworthiness. <b>Strong Promoter Support:</b> The rating is underpin…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
**Credit Rating:** CARE Ratings has reaffirmed the company's top-tier **'CARE AAA; Stable'** rating for its long-term bank facilities and **'CARE A1+'** for short-term instruments, citing strong promoter support. **FY25 Performance:** The company reported a **net loss of ₹98 cror…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's long-term rating at **'CARE AAA; Stable'** and short-term rating at **'CARE A1+'**. These are the highest possible ratings, indicating minimal credit risk. Key strengths cited include strong promoter support from the Cyrus Poonawalla grou…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
CARE Ratings has reaffirmed the company's highest long-term rating at <b>'CARE AAA; Stable'</b> and short-term rating at <b>'CARE A1+'</b>. A new rating of <b>'CARE AA+; Stable'</b> was assigned to the upcoming Perpetual Debt issue of ₹1,500 Crore. The company reported strong AUM…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
• CARE Ratings has reaffirmed the company's highest long-term rating of 'CARE AAA; Stable' and short-term rating of 'CARE A1+'. A new rating of 'CARE AA+; Stable' was also assigned to Perpetual Debt of ₹1,500 crore. • The rating is underpinned by strong promoter support from the…
Poonawalla Fincorp Limited · POONAWALLA · NSE ·
**Credit Rating:** CARE Ratings reaffirmed its highest 'CARE AAA; Stable' rating for long-term debt but assigned a new 'CARE AA+; Stable' rating to ₹1,500 Crore of Perpetual Debt. **Financial Performance:** The company reported a net loss of ₹-98 Crore for the fiscal year ending…
Glenmark Pharmaceuticals Limited · GLENMARK · NSE ·
Announced the launch of GLIPIQ® (Semaglutide) in India for the management of Type 2 Diabetes. The drug is strategically priced to be highly affordable, with a weekly treatment cost starting at ₹325, aiming to set a "new benchmark in affordability" for GLP-1 therapy. This launch i…
Glenmark Pharmaceuticals Limited · GLENMARK · NSE ·
Glenmark has launched GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes. The drug is priced disruptively, with a weekly treatment cost starting at ₹325, aiming to make advanced diabetes therapy more affordable. The launch is supported by a new patient support p…
Glenmark Pharmaceuticals Ltd · GLENMARK · BSE ·
Glenmark has launched **GLIPIQ® (Semaglutide)** in India for the management of Type 2 Diabetes. The company is setting a **new benchmark in affordability** for advanced diabetes therapy, with weekly treatment starting at ₹325. This strategic launch aims to penetrate the high-grow…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
<b>Rating Reaffirmed:</b> CARE Ratings has reaffirmed the company's long-term rating at <b>'CARE AAA; Stable'</b>, citing strong promoter support from the Cyrus Poonawalla group. <b>FY25 Financials:</b> The company reported a <b>net loss of ₹98 crore for FY25</b>, a sharp contras…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
**Rating Reaffirmed:** CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating for the company's Long-term Bank Facilities (₹27,520 Cr) and NCDs, and 'CARE A1+' for its Commercial Paper (₹7,500 Cr). **New Rating Assigned:** A new rating of 'CARE AA+; Stable' has been as…
Poonawalla Fincorp Ltd · POONAWALLA · BSE ·
• <b>Top-Tier Rating Reaffirmed:</b> CARE Ratings has reaffirmed its highest long-term rating of 'CARE AAA; Stable' on the company's bank facilities and debt instruments, and 'CARE A1+' on its Commercial Paper. • <b>Strong Promoter Backing:</b> The rating is driven by strong supp…
Innovassynth Technologies (India) Ltd · 533315 · BSE ·
The company has changed its official website to <b>www.innovassynth.com</b> as a result of a major corporate restructuring. The restructuring involved a <b>merger</b> and a subsequent <b>name change</b> from "Innovassynth Investments Limited" to "Innovassynth Technologies (India)…
Innovassynth Technologies (India) Ltd · 533315 · BSE ·
The company has launched a new official website: <b>www.innovassynth.com</b>, replacing the old one. This follows a significant corporate restructuring through a "Scheme of Merger by Absorption". As a result of the merger, the company's name has been changed from "Innovassynth In…
Innovassynth Technologies (India) Ltd · 533315 · BSE ·
The company has officially changed its name from **Innovassynth Investments Limited** to **Innovassynth Technologies (India) Limited**. This follows a merger by absorption, transforming the company from an investment firm into an operating technology entity. This is a highly mate…
